GeckoSystems Intl. Corp. (PINKSHEETS: GCKO) (http://www.geckosystems.com/) announced in their press release today that since Sprint Nextel Corporation has finalized their contractual terms and conditions, Gecko can more expediently complete their first elder care robot trials. This announcement follows their press release last month stating they were in negotiations with a Fortune 500 company. As a result of this agreement , Gecko’s elder care robot trial participants will receive special pricing from Sprint Nextel; the trials have been underway since late 2009.
GCKO opened yesterday at $0.015 and closed at $0.0165 which is an increase of 10%; the volume over the past few days has also been rising. I wonder if this diamond in the rough is soon to be a polished stone. Better yet, a flawless polished stone. I'm holding my position long term.
Remember that since GCKO is a penny stock, it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. It is important to do your own Due Diligence before investing your money in this or any other stock and do not base your buy/sell decisions on the opinions and comments of LA Stock Talk.
LA
Thursday, July 22, 2010
Wednesday, July 21, 2010
Cannabis Science, Inc. (OTCBB:CBIS)
Cannabis Science, Inc. is a pioneering U.S. biotech company developing pharmaceutical cannabis products.
California’s Proposition 19, the legalization of cannabis products, has been a heavily debated topic as of late. If you have trouble sleeping go to the following web site to read all about Proposition 19 - http://www.sos.ca.gov/elections/ballot-measures/qualified-ballot-measures.htm. If that doesn’t put you to sleep, the website includes several other California propositions you can read about.
As I delved into the mountains of information surrounding the topic I came across a company called Cannabis Science, Inc. (CBIS). Their website defines the company as a pioneering U.S. biotech company developing pharmaceutical cannabis products. I perused their press releases and below is my synopsis of several of them along with other information. My synopsis only includes the information from the press releases that I chose to share in this posting. If you would like to review the full press release go to the CBIS website: http://www.cannabisscience.com
March 2, 1010
CBIS announced that they have the results of their survey of more than 1,300 individuals with Post Traumatic Stress Disorder (PTSD) which included a large cohort of veterans. They also reported several prospective drugs for FDA clinical trials. As a result of the survey data and other extensive studies, CBIS said they now have the data necessary their first application for a PTSD drug for FDA clinical trials; the Company plans to hire a group of FDA specialists to handle their first FDA filings.
March 4, 2010
CBIS announced that it has set its second FDA drug target on the $20 Billion "Chronic Pain" market and plan to launch a new survey of cannabis use by chronic pain patients to gather additional first hand information from all chronic pain suffers. You can find a list of drug targets on the CBIS website.
May 24, 2010
CBIS acquired 100% of a private company with two revenue producing operations, an organic medical cannabis growing facility and a medical cannabis dispensary for patients in Colorado in accordance with state laws. This added income provides CBIS with a revenue stream much sooner than otherwise possible and they plan to expand them by acquiring a larger facility which will enhance their ability to develop pharmaceutical cannabis products for FDA approval. The company issued 2.4 million shares to pay for the acquisition of the operations and as compensation for a management contract. Currently, there are 64,570,574 shares outstanding and management expects to retire most of its debt by the end of June 2010 to eliminate a major source of risk. The former owner, Mr. Adam Pasquale, is joining the CBIS as Director of Horticulture with responsibility for managing these operations and the implementation of CBIS’s plan to expand these areas nationally, as the laws allow. As of July 21, 2010, they still have 64,570,574 shares outstanding.
June 1, 2010
Dr. Robert Melamede said that CBIS is negotiating the purchase of a privately held biopharmaceutical company that owns complementary patented intellectual property for specific clinical stage cannabinoid products and uses. He went on to say that they filed a preliminary patent disclosure with the University of Colorado regarding the additional new technology they intend to develop through the targeted private company acquisitions and plan to hire a patent attorney to help with the University disclosure and ultimate patent filings. Additionally, they are working with FDA consultants in their quest to obtain FDA approval for several new pharmaceutical products they believe can be derived from this deal. Dr. Melamede said efforts to identify and consolidate various new technologies aimed at developing pharmaceutical cannabis products for critical illnesses and worldwide distribution would continue.
June 28, 2010
CBIS said they viewed UK-based GW Pharmaceuticals receipt of a $15 million milestone payment from Bayer as an important signpost for the continued validation of medical cannabis. According to the press release, the payment to GW was based on the UK Government's approval of GW Pharmaceuticals Sativex(R), an "Oromucosal Spray" tincture for the treatment of spasticity due to Multiple Sclerosis (MS) and is the first cannabis drug to be approved in the UK. According to Piper Jaffary analysts, peak sales for Sativex(R) could reach $180 million in Europe and Canada combined. The release mentioned that the US FDA previously granted GW a Phase III IND for Sativex, and a Phase IIb/III trial for cancer pain, GW’s receipt of an 18 million dollar licensing fee from Otsuka for the US rights and the receipt of several million from licensing fees from Almiral of Spain for the European rights outside of the UK which included payment for the work necessary to obtain regulatory approval. In a nutshell, it appears that Big Pharma has recognized the potential of this industry and wants a piece of the action. Additionally, the approval sativex(R) by the FDA could potentially lead to the fast-tracking of other whole cannabis extracts.
June 29, 2010
Dr. Robert Melamede PhD, President and CEO of CBIS, said that the expansion of the internal production of CBIS at their Montana Pain Management (MPM) facility would allow them to expand their patient base by 100 new clients each month and help advance their objectives in developing pharmaceutical applications for medical CBIS. He further stated that the coupling of the internal production facility, MPM’s agricultural staff and CBIS’s scientists and commercial production staff aggressively positions CBIS to be a key player in the developing national medical CBIS industry. The release also mentioned that Montana officials were working with Rick Rosio, President and CEO of MPM, to develop policies that protect patients and help them access the medicines they need. An early June press release announced the acquisition of MPM by CBIS in June 2010.
July 8, 2010
CBIS announced their execution of a long-term lease on a 9,500 square foot facility in Denver, Colorado, that will become its corporate offices, as well as serving as a research facility for developing, testing, and production in compliance with the new Colorado laws regulating medical marijuana in the state. What intrigued me was the mention of the “long-term” lease.
According to the CBIS website, several states have already approved cannabis for medicinal approval. From all indications, California is well on their way to approving Proposition 19. If it passes in California and has a positive impact on their troubled economic condition, I wonder how many other troubled states would follow suit? If it does, it appears as though CBIS is doing everything possible to hit the ground running when the time comes.
California’s Proposition 19, the legalization of cannabis products, has been a heavily debated topic as of late. If you have trouble sleeping go to the following web site to read all about Proposition 19 - http://www.sos.ca.gov/elections/ballot-measures/qualified-ballot-measures.htm. If that doesn’t put you to sleep, the website includes several other California propositions you can read about.
As I delved into the mountains of information surrounding the topic I came across a company called Cannabis Science, Inc. (CBIS). Their website defines the company as a pioneering U.S. biotech company developing pharmaceutical cannabis products. I perused their press releases and below is my synopsis of several of them along with other information. My synopsis only includes the information from the press releases that I chose to share in this posting. If you would like to review the full press release go to the CBIS website: http://www.cannabisscience.com
March 2, 1010
CBIS announced that they have the results of their survey of more than 1,300 individuals with Post Traumatic Stress Disorder (PTSD) which included a large cohort of veterans. They also reported several prospective drugs for FDA clinical trials. As a result of the survey data and other extensive studies, CBIS said they now have the data necessary their first application for a PTSD drug for FDA clinical trials; the Company plans to hire a group of FDA specialists to handle their first FDA filings.
March 4, 2010
CBIS announced that it has set its second FDA drug target on the $20 Billion "Chronic Pain" market and plan to launch a new survey of cannabis use by chronic pain patients to gather additional first hand information from all chronic pain suffers. You can find a list of drug targets on the CBIS website.
May 24, 2010
CBIS acquired 100% of a private company with two revenue producing operations, an organic medical cannabis growing facility and a medical cannabis dispensary for patients in Colorado in accordance with state laws. This added income provides CBIS with a revenue stream much sooner than otherwise possible and they plan to expand them by acquiring a larger facility which will enhance their ability to develop pharmaceutical cannabis products for FDA approval. The company issued 2.4 million shares to pay for the acquisition of the operations and as compensation for a management contract. Currently, there are 64,570,574 shares outstanding and management expects to retire most of its debt by the end of June 2010 to eliminate a major source of risk. The former owner, Mr. Adam Pasquale, is joining the CBIS as Director of Horticulture with responsibility for managing these operations and the implementation of CBIS’s plan to expand these areas nationally, as the laws allow. As of July 21, 2010, they still have 64,570,574 shares outstanding.
June 1, 2010
Dr. Robert Melamede said that CBIS is negotiating the purchase of a privately held biopharmaceutical company that owns complementary patented intellectual property for specific clinical stage cannabinoid products and uses. He went on to say that they filed a preliminary patent disclosure with the University of Colorado regarding the additional new technology they intend to develop through the targeted private company acquisitions and plan to hire a patent attorney to help with the University disclosure and ultimate patent filings. Additionally, they are working with FDA consultants in their quest to obtain FDA approval for several new pharmaceutical products they believe can be derived from this deal. Dr. Melamede said efforts to identify and consolidate various new technologies aimed at developing pharmaceutical cannabis products for critical illnesses and worldwide distribution would continue.
June 28, 2010
CBIS said they viewed UK-based GW Pharmaceuticals receipt of a $15 million milestone payment from Bayer as an important signpost for the continued validation of medical cannabis. According to the press release, the payment to GW was based on the UK Government's approval of GW Pharmaceuticals Sativex(R), an "Oromucosal Spray" tincture for the treatment of spasticity due to Multiple Sclerosis (MS) and is the first cannabis drug to be approved in the UK. According to Piper Jaffary analysts, peak sales for Sativex(R) could reach $180 million in Europe and Canada combined. The release mentioned that the US FDA previously granted GW a Phase III IND for Sativex, and a Phase IIb/III trial for cancer pain, GW’s receipt of an 18 million dollar licensing fee from Otsuka for the US rights and the receipt of several million from licensing fees from Almiral of Spain for the European rights outside of the UK which included payment for the work necessary to obtain regulatory approval. In a nutshell, it appears that Big Pharma has recognized the potential of this industry and wants a piece of the action. Additionally, the approval sativex(R) by the FDA could potentially lead to the fast-tracking of other whole cannabis extracts.
June 29, 2010
Dr. Robert Melamede PhD, President and CEO of CBIS, said that the expansion of the internal production of CBIS at their Montana Pain Management (MPM) facility would allow them to expand their patient base by 100 new clients each month and help advance their objectives in developing pharmaceutical applications for medical CBIS. He further stated that the coupling of the internal production facility, MPM’s agricultural staff and CBIS’s scientists and commercial production staff aggressively positions CBIS to be a key player in the developing national medical CBIS industry. The release also mentioned that Montana officials were working with Rick Rosio, President and CEO of MPM, to develop policies that protect patients and help them access the medicines they need. An early June press release announced the acquisition of MPM by CBIS in June 2010.
July 8, 2010
CBIS announced their execution of a long-term lease on a 9,500 square foot facility in Denver, Colorado, that will become its corporate offices, as well as serving as a research facility for developing, testing, and production in compliance with the new Colorado laws regulating medical marijuana in the state. What intrigued me was the mention of the “long-term” lease.
According to the CBIS website, several states have already approved cannabis for medicinal approval. From all indications, California is well on their way to approving Proposition 19. If it passes in California and has a positive impact on their troubled economic condition, I wonder how many other troubled states would follow suit? If it does, it appears as though CBIS is doing everything possible to hit the ground running when the time comes.
Thursday, July 8, 2010
GeckoSystems (GCKO)
7/8/10 – GeckoSystem Int’l announced that the international market research firm, Markets and Markets, forecasted $21 billion in annual sales for the global service robotics market by end of 2014.
06/30/10 - GeckoSystem Int’l announced that they are now soliciting retail dealers for their first product, an elder care capable personal assistant robot, the CareBot™. The press release also mentioned the article in the January 2007 issue of "Scientific American," entitled "A Robot in Every Home" authored by Bill Gates which includes discussions as to why he expects that reality sooner than later.
6/21/1010 - GeckoSystem Int’l announced that a major US telecommunications company considers GeckoSystems to have strategic fit within their New Solutions Group. Due to on-going negotiations, the name of the future partner was not disclosed.
I still firmly believe that the future looks promising for the CareBot™ and this device will have a significant impact on the lifestyles of our future generations of elderly. The timing for setting up distributorships now, in my opinion, is aligned with the needs of the aging baby boomer population. Who knows, a CareBot™ in th e homes of aging baby boomers could be a part of the realm of reality projected by Bill Gates. As soon as one of the “big boys” discovers the potential of this stock and begins making purchases, the doors for the other big players will swing wide open and the share price we see today will be left behind in the dust of the stampede.
The future prospect of the CareBot™ continues to excite me and I hope I can acquire more GCKO stock before this hidden gem is uncovered. It closed green today – is the steam starting to build?
Remember, since GCKO is a penny stock it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. Remember the importance of doing your own Due Diligence before investing your money in this or any other stock and do not base your Buy/Sell decisions on the opinions and comments of LA Stock Talk.
Disclosure: LA Long GCKO
06/30/10 - GeckoSystem Int’l announced that they are now soliciting retail dealers for their first product, an elder care capable personal assistant robot, the CareBot™. The press release also mentioned the article in the January 2007 issue of "Scientific American," entitled "A Robot in Every Home" authored by Bill Gates which includes discussions as to why he expects that reality sooner than later.
6/21/1010 - GeckoSystem Int’l announced that a major US telecommunications company considers GeckoSystems to have strategic fit within their New Solutions Group. Due to on-going negotiations, the name of the future partner was not disclosed.
I still firmly believe that the future looks promising for the CareBot™ and this device will have a significant impact on the lifestyles of our future generations of elderly. The timing for setting up distributorships now, in my opinion, is aligned with the needs of the aging baby boomer population. Who knows, a CareBot™ in th e homes of aging baby boomers could be a part of the realm of reality projected by Bill Gates. As soon as one of the “big boys” discovers the potential of this stock and begins making purchases, the doors for the other big players will swing wide open and the share price we see today will be left behind in the dust of the stampede.
The future prospect of the CareBot™ continues to excite me and I hope I can acquire more GCKO stock before this hidden gem is uncovered. It closed green today – is the steam starting to build?
Remember, since GCKO is a penny stock it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. Remember the importance of doing your own Due Diligence before investing your money in this or any other stock and do not base your Buy/Sell decisions on the opinions and comments of LA Stock Talk.
Disclosure: LA Long GCKO
Subscribe to:
Posts (Atom)